Tobira, Regado merged business will focus on NASH therapies
This article was originally published in Scrip
Tobira Therapeutics, which last year discarded IPO plans, will merge its business with publically traded Regado Biosciences in an all-stock transaction, creating one company focused on the development of novel treatments for liver and inflammatory diseases.
You may also be interested in...
A selection of features you might have missed from the first six months of 2020, covering key topics from COVID-19 strategies in medtech to an analysis of pipeline focus areas across the pharma sector. Click on each section to get the full story behind the data.
The two-part vaccine becomes the second against Ebola to get approval. Janssen is now collaborating with the World Health Organization on vaccine pre-qualification to get it to people in need.
Johan Van Hoof, global head of vaccines at Janssen, talks to In Vivo about the company’s platform, how it is approaching COVID-19 research and the impact of today’s global pandemic on the future of vaccine R&D.